coronavirus

Amnesty says COVID jab producers are causing human rights crisis

Amnesty International has slammed the six pharma companies behind the bulk of COVID-19 vaccine supplies of for not agreeing to waive their intellectual property rights and share the technology behind them. The charity says AstraZeneca, BioNTech, Johnson & Johnson, Moderna, Novavax, and Pfizer are fuelling an “unprecedented human rights crisis” as a result and their …

Amnesty says COVID jab producers are causing human rights crisis Read More »

Big pharma fuelling human rights crisis over Covid vaccine inequity – Amnesty

Six companies warned not to put profit before lives as report shows less than 1% of almost 6bn doses have gone to low-income countries Amnesty International has accused six pharmaceutical companies that have developed Covid-19 vaccines of fuelling a global human rights crisis, citing their refusal to sufficiently waive intellectual property rights, share vaccine technology …

Big pharma fuelling human rights crisis over Covid vaccine inequity – Amnesty Read More »

PhRMA awards $150,000 to community-based projects aimed at tackling inequities in access to COVID-19 testing, vaccines and therapeutics

The COVID-19 pandemic has widened health disparities, including the gap in average life expectancy and outcomes for many chronic diseases. These inequities in health status and outcomes among racial and ethnic groups often are rooted in community-level factors like where and how we live, work, and play; inherent bias; lack of adequate coverage and access …

PhRMA awards $150,000 to community-based projects aimed at tackling inequities in access to COVID-19 testing, vaccines and therapeutics Read More »

RwHealth, the Artificial Intelligence provider for the NHS, promises to transform healthcare

RwHealth, the leading provider of Artificial Intelligence to the healthcare industry, has today reported 160 per cent year-on-year growth as its data-led solutions are increasingly embraced by NHS trusts, private healthcare providers and major pharmaceutical companies.   RwHealth’s unique Data Science Platform combines Artificial Intelligence (AI), Machine Learning and Data Science to give healthcare providers …

RwHealth, the Artificial Intelligence provider for the NHS, promises to transform healthcare Read More »

Pfizer, BioNTech prep low-dose COVID jab filing for kids aged 5 to 11

With positive phase 2/3 results for their COVID-19 vaccine Comirnaty in hand for the five to 11 age group, Pfizer and BioNTech are planning to move swiftly ahead with a filing for emergency use that could be approved in a matter of weeks. The data is the first generated with any COVID-19 vaccine in this …

Pfizer, BioNTech prep low-dose COVID jab filing for kids aged 5 to 11 Read More »

Pfizer, BioNTech prep low-dose COVID jab filing for kids aged 5 to 11

With positive phase 2/3 results for their COVID-19 vaccine Comirnaty in hand for the five to 11 age group, Pfizer and BioNTech are planning to move swiftly ahead with a filing for emergency use that could be approved in a matter of weeks. The data is the first generated with any COVID-19 vaccine in this …

Pfizer, BioNTech prep low-dose COVID jab filing for kids aged 5 to 11 Read More »

Ministers told to bar EU from UK trial data in vaccines row

England’s deputy medical chief asked for data to be withheld unless British vaccine guinea pigs allowed to travel abroad • Coronavirus – latest updates• See all our coronavirus coverage England’s deputy chief medical officer asked ministers to withhold all UK clinical trial data from the EU if European countries continued to deny entry to British …

Ministers told to bar EU from UK trial data in vaccines row Read More »

Racial Disparities in COVID-19 Impacts and Vaccinations for Children

COVID-19 has disproportionately negatively affected the physical and mental health, academic growth, and economic security of children of color. At the same time, the limited data available to date suggest some children of color may be less likely to receive a COVID-19 vaccine, leaving them at elevated risk as the virus continues to spread and …

Racial Disparities in COVID-19 Impacts and Vaccinations for Children Read More »

Ahead of FDA adcomm, Pfizer, Moderna say COVID jab efficacy dips

Pfizer and Moderna have both reported data that they say backs up the need for booster shots of their COVID-19 vaccines ahead of an FDA advisory committee meeting tomorrow, although the regulator seems less convinced. Documents published ahead of the panel by the FDA reviewers suggest that there is some evidence from observational studies that …

Ahead of FDA adcomm, Pfizer, Moderna say COVID jab efficacy dips Read More »

EU ‘negotiating with Valneva’ over COVID-19 vaccine contract

The European Commission is reportedly in advanced discussions with French biotech Valneva about picking up the contract to supply COVID-19 vaccines that was terminated by the UK government this week. A French government source told Reuters that the EU is considering using the VLA2001 vaccine as part of its booster campaign plans, along with a …

EU ‘negotiating with Valneva’ over COVID-19 vaccine contract Read More »

UK poised to announce booster COVID jabs for over-50s

The UK government is due to announce a large-scale booster vaccine campaign against COVID-19 for all adults aged 50 and over later today, adding to its plan for third doses for people with weakened immune systems. The plan will see millions of doses of the Pfizer/BioNTech mRNA vaccine administered across the autumn and winter to …

UK poised to announce booster COVID jabs for over-50s Read More »

Valneva slumps as UK dumps €1.4bn order for COVID-19 jab

The UK has terminated its order for up to 190 million doses of a COVID-19 vaccine developed by French biotech company Valneva, accusing it of breaching their supply agreement. Valneva said it “strenuously denies” that allegation, but added that the €1.4 billion ($1.65 billion) contract does provide the UK government with the right to exit …

Valneva slumps as UK dumps €1.4bn order for COVID-19 jab Read More »

UK cancels Covid vaccine deal with French firm Valneva

Government serves notice to terminate contract over allegations of a ‘breach of obligations’ Coronavirus – latest updates See all our coronavirus coverage The UK government is to pull out of a deal with the French pharmaceutical company Valneva to purchase its Covid-19 vaccination, the company has said. The move will come as a blow to …

UK cancels Covid vaccine deal with French firm Valneva Read More »

A year that changed the world – and medical companies’ fortunes

While Covid sent many firms to the wall, others prospered by spotting opportunities, from test kits to mask coatings The pandemic has taken a heavy toll on business, gutting high streets as familiar names fell into receivership. But for some less well-known firms, the past 18 months have been transformational. Those that have thrived did …

A year that changed the world – and medical companies’ fortunes Read More »

BioNTech to seek approval for Covid jabs for younger children

Company behind Pfizer vaccine expected to file results of trial of five- to 11-year-olds with regulator soon Coronavirus – latest updates See all our coronavirus coverage The German company BioNTech, which developed the Pfizer vaccine, expects to seek approval from regulators for Covid jabs suited for younger children as early as mid-October, its founders have …

BioNTech to seek approval for Covid jabs for younger children Read More »

MHRA clears third doses of AZ, Pfizer COVID jabs

The UK medicines regulator has cleared the use of a third dose of both the AstraZeneca and Pfizer COVID-19 vaccines, in readiness for a possible booster campaign ahead of the winter months. The decision means there is now no impediment to starting a booster drive – assuming the Joint Committee on Vaccination and Immunisation (JCVI) …

MHRA clears third doses of AZ, Pfizer COVID jabs Read More »

Pfizer accused of holding Brazil ‘to ransom’ over vaccine contract demands

Leaked supply document reveals clauses to protect US pharma company from legal action in the event of serious side-effects Coronavirus – latest updates See all our coronavirus coverage Pfizer has been accused of holding Brazil “to ransom” over demands to shield itself from possible vaccine side-effect lawsuits in its contract to supply the country with …

Pfizer accused of holding Brazil ‘to ransom’ over vaccine contract demands Read More »

A year and a half later: The biopharmaceutical industry remains committed to beating COVID-19

Since the start of the pandemic, America’s biopharmaceutical companies have worked around the clock to research, develop and manufacture treatments and vaccines to fight COVID-19. Already, we’ve made unprecedented progress; three vaccines are currently available for protection against COVID-19 in the U.S, one of which was recently approved by the U.S. Food and Drug Administration …

A year and a half later: The biopharmaceutical industry remains committed to beating COVID-19 Read More »

Gates Foundation ramps up funding to Exscientia in COVID project

The Bill & Melinda Gates Foundation must have liked what it saw in an initial collaboration with Exscientia to find new antivirals for COVID-19 and related diseases. Two months after providing initial funding of $1.5 million to get the ball rolling, the philanthropic organisation has now pledged $35 million in funding to a four-year project …

Gates Foundation ramps up funding to Exscientia in COVID project Read More »

Extreme Heat and Racial Health Equity

During the summer, the United States reported record extreme heat events across the country. While extreme heat and other hazardous weather events have implications for everyone, growing research shows that they disproportionately affect low-income people and people of color due to underlying social inequities and structural discrimination.

AZ CEO Soriot urges caution on COVID booster doses

The UK should think twice before backing widespread use of COVID-19 booster vaccinations, as to do so could place unnecessary burden on the NHS over the winter, according to AstraZeneca chief executive Pascal Soriot. In a letter to The Daily Telegraph newspaper with AZ’s head of biopharma R&D Mene Pangalos, Soriot write that the UK …

AZ CEO Soriot urges caution on COVID booster doses Read More »

UK pledges £5.4bn to NHS to ease COVID-19 treatment backlog

NHS England will get an extra £5.4 billion ($7.5 billion) in funding over the next six months to respond to COVID-19 and address a backlog in care caused by the pandemic, according to the UK government. The total includes £1 billion to get delivery of routine surgeries and treatments to patients delayed by COVID-19 back …

UK pledges £5.4bn to NHS to ease COVID-19 treatment backlog Read More »

EMA looks at booster data for Pfizer/BioNTech COVID-19 jab

The EU regulator has started to review a marketing application filed by Pfizer and BioNTech for a third, booster dose of their Comirnaty COVID-19 vaccine given six months after the first course to people aged 16 and over. The EMA’s CHMP human medicines committee will carry out an accelerated review of the application, which comes …

EMA looks at booster data for Pfizer/BioNTech COVID-19 jab Read More »

Australian Novavax trial participants remain unrecognised by vaccine register

Covid vaccination status of hundreds in limbo because the US company’s jab is yet to be approved in Australia Vaccine rollout tracker; get our free news app; get our morning email briefing Australians who participated in clinical trials of the Novavax Covid vaccine are being told their vaccinations cannot currently be recognised on Australia’s immunisation …

Australian Novavax trial participants remain unrecognised by vaccine register Read More »

UK CMOs to advise on COVID-19 jabs for 12- 15-year-olds

The government has asked the UK’s four chief medical officers (CMOs) to advise on possible rollout of COVID-19 jabs for people aged 12 to 15 after the JCVI said health benefits ‘marginally outweigh’ potential risk in this group.

The impact of monoclonal antibodies and COVID-19 recovery

As the United States and world continue to fight the COVID-19 pandemic, America’s biopharmaceutical research companies continue to do our part in fighting this deadly virus. Decades of scientific innovation have allowed biopharmaceutical researchers to respond quickly and continue to research and develop treatments and vaccines for COVID-19. Importantly, the best strategy to prevent infection …

The impact of monoclonal antibodies and COVID-19 recovery Read More »

Japan’s Moderna Covid vaccine rollout hit by recall and contamination scares

Foreign materials including stainless steel identified in batches of Covid-19 vaccine though no safety or efficacy issues have been reported The Moderna coronavirus vaccine programme in Japan has been hit by a series of contamination incidents, prompting it to recall 1.63m doses found to contain metal fragments. Other potential contaminants have been identified in separate …

Japan’s Moderna Covid vaccine rollout hit by recall and contamination scares Read More »

Major shareholder’s Rolls-Royce grumble could rumble on

Vague demand for board refresh from Causeway likely a hangover from £2bn rights issue The last time Rolls-Royce had an US activist fund on its tail, the aero-engine manufacturer took the unusual step of inviting one of its representatives onto the board. ValueAct Capital was judged to have constructive ideas and useful industry expertise. The …

Major shareholder’s Rolls-Royce grumble could rumble on Read More »

Recognizing National Immunization Awareness Month

Vaccines have played a critical role in reducing the spread of, and in some cases, eliminating the threat of many devastating infectious diseases. They are often cited as second only to clean drinking water in leading to some of the most impactful public health advances in history, including the eradication of smallpox globally and measles, …

Recognizing National Immunization Awareness Month Read More »

GSK takes SK bio-partnered COVID jab into phase 3

As a top vaccine maker, GlaxoSmithKline has been a laggard in the COVID-19 vaccine race, but has put on a late burst of speed with a start of phase 3 trials of a second candidate that will be compared directly to the AstraZeneca shot. The move follows phase 1/2 results with SK bio’s GBP510, which …

GSK takes SK bio-partnered COVID jab into phase 3 Read More »

Views Of COVID-19 Vaccines Among LGBT Adults

This new analysis examines the experiences of LGBT adults from the July COVID-19 Vaccine Monitor and finds that as a group they are more likely to be vaccinated for COVID-19 and less likely to view getting the vaccine as a health risk compared to non-LGBT adults. A larger share of LGBT adults than non-LGBT adults …

Views Of COVID-19 Vaccines Among LGBT Adults Read More »

Two New KFF Reports Take a Closer Look at the COVID-19 Pandemic and the LGBT Community, From the Impact on Mental Health to Vaccination Status

Two new KFF reports provide new and updated data on the experiences of lesbian, gay, bisexual and transgender (LGBT) people during the COVID-19 pandemic, featuring data showing the impact on mental health and COVID-19 Vaccine Monitor data on vaccine uptake within the community. The two reports add important context to the limited but growing body…More

UK real-world study finds COVID-19 jab protection wanes

A study has found evidence that protection from the AstraZeneca and Pfizer/BioNTech COVID-19 vaccines starts fall off after a few months, but a UK government advisor says there’s no need to rush into a large-scale booster campaign. The results of the ZOE COVID study found that initial protection against infection a month after the second …

UK real-world study finds COVID-19 jab protection wanes Read More »

FDA grants full approval to Pfizer/BioNTech COVID jab

Pfizer and BioNTech’s COVID-19 vaccine was the first to get emergency use authorisation (EUA) from the FDA, and has also become the first to get full regulatory approval in the US. The regulator has cleared the vaccine – now officially given the trade name Comirnaty – to prevent COVID-19 in people aged 16 or more, …

FDA grants full approval to Pfizer/BioNTech COVID jab Read More »

COVID prompts another milestone, as India clears first DNA vaccine

The COVID-19 pandemic accelerated the development of mRNA-based vaccines, and its influence has now extended to DNA-based shots as well, with Zydus Cadila’s ZyCoV-D getting emergency use authorisation in India. This is the first DNA vaccine to ever receive regulatory authorisation anywhere in the world, the first COVID-19 jab approved in India to treat children …

COVID prompts another milestone, as India clears first DNA vaccine Read More »

Lessons learned from the Covid vaccine development process

As the world’s focus has turned to getting the COVID-19 vaccines out as widely and rapidly as possible, it’s easy to almost forget about the incredible global effort that developed them in record time. But it is important to take some time to reflect on the process that got us here, so that we can …

Lessons learned from the Covid vaccine development process Read More »

PROVENT trial puts AZ COVID antibody combo back on track

AstraZeneca’s AZD7442 has shown that it can prevent COVID-19 infection when given to healthy patients – the first time this has been demonstrated by a long-acting antibody-based drug. The results of the almost 5,200-patient PROVENT study show that pre-exposure prophylaxis using the antibody combination reduced the risk of developing symptomatic COVID-19 by 77% compared to …

PROVENT trial puts AZ COVID antibody combo back on track Read More »

UK approves rollout of ‘first of its kind’ Covid antibody treatment

Ronapreve can be used to treat symptoms of acute infection after successful clinical trials Coronavirus – latest updates See all our coronavirus coverage The medicines regulator has approved use of the first treatment in the UK using artificial antibodies to prevent and fight Covid-19. The health secretary, Sajid Javid, said approval of the first drug …

UK approves rollout of ‘first of its kind’ Covid antibody treatment Read More »

KFF COVID-19 Vaccine Monitor: The Impact Of The Coronavirus Pandemic On The Wellbeing Of Parents And Children

This report examines the impact of the COVID-19 pandemic on the wellbeing of parents and children. It finds that more than one-third of parents say their child fell behind academically or in their social and emotional development as a result of the pandemic. This report also examines the mental health and wellbeing of parents whose …

KFF COVID-19 Vaccine Monitor: The Impact Of The Coronavirus Pandemic On The Wellbeing Of Parents And Children Read More »

Four in Ten Parents of School-Aged Children Say a Child Fell Behind Academically Due to the COVID-19 Pandemic

Four in Ten Parents Say Someone in Their Household Left a Job or Worked Fewer Hours to Care for Their Children, Including Higher Shares of Black, Hispanic, and Lower-income Parents As a result of the pandemic, about four in ten (39%) parents of school-aged children (ages 5-17) say at least one of their children fell…More

Amid Actemra shortage, WHO asks Roche to ensure equitable access

Roche’s arthritis drug Actemra has become a key treatment for people with severe COVID-19, leading to shortages, and the World Health Organisation (WHO) wants the company to ensure that supplies don’t just go to wealthy countries. Earlier this week Roche’s Genentech unit said it was facing unprecedented demand for Actemra (tocilizumab) – known as RoActemra …

Amid Actemra shortage, WHO asks Roche to ensure equitable access Read More »

Welcome to the COVIDome, a new tool for COVID-19 R&D

Take a cohort of people hospitalised with COVID-19 and a group of negative controls, carry out extensive biological profiling of both groups and place all the information in a database. What do you get? A new R&D toolkit called the COVIDome, which has been shared by its developers in the hope that it could accelerate …

Welcome to the COVIDome, a new tool for COVID-19 R&D Read More »

MHRA clears Moderna COVID vaccine for 12 to 17 year olds

The Moderna COVID-19 vaccine has become the second jab to be authorised for use in England, Scotland and Wales in children aged 12 to 17 after getting the nod from the Medicines and healthcare products Regulatory Agency (MHRA). It joins the Pfizer/BioNTech vaccine in being an option for that age group, having been approved in …

MHRA clears Moderna COVID vaccine for 12 to 17 year olds Read More »

Pfizer, BioNTech file for FDA approval of COVID booster shot

Pfizer and BioNTech have formally asked for FDA approval of a third dose of their COVID-19 vaccine BNT162b2 in people aged over 16, as the US prepares to get its booster campaign underway. The two companies have submitted data from a phase 1 trial in support of the booster dose to the US regulator, and …

Pfizer, BioNTech file for FDA approval of COVID booster shot Read More »

Merck kicks off oral COVID-19 antiviral filing in Canada

Health Canada has started a rolling review of Merck & Co’s molnupiravir, an oral antiviral therapy treatment for COVID-19 partnered with Ridgeback Biotherapeutics. The Canadian regulator will start reviewing early safety, quality and efficacy data for the drug while late-stage clinical trials are still underway, in the hope of approving the drug quickly of results …

Merck kicks off oral COVID-19 antiviral filing in Canada Read More »

UK adults asked to record coughs to improve COVID detection

Researchers in the UK are asking adults who have taken a COVID-19 test in the last 72 hours to record themselves coughing, breathing and speaking to help develop new ways to detect infection. The aim is to develop algorithms that could be used to detect COVID-19 remotely – for example before a PCR or lateral …

UK adults asked to record coughs to improve COVID detection Read More »

Drug firms poised to make billions of dollars from Covid booster jabs

Sales of BioNTech, Moderna and Pfizer drugs could rival $6bn-a-year market for flu vaccines, say analysts Coronavirus – latest updates See all our coronavirus coverage The drug companies Pfizer, BioNTech and Moderna are poised to make billions of dollars from Covid-19 booster jabs this autumn, with analysts estimating that sales could rival the $6bn-a-year market …

Drug firms poised to make billions of dollars from Covid booster jabs Read More »

Children Head Back to School Amid an Ongoing Pandemic That Has Had Significant Effects on Their Health and Well-Being

As students head back to in-person school this fall, a new KFF brief highlights the effects of the ongoing pandemic on the health and well-being of children, including missed routine vaccinations and preventive care, mental health challenges and economic setbacks that can influence health. There had been over 4 million COVID-19 cases among children as…More

Back to School amidst the New Normal: Ongoing Effects of the Coronavirus Pandemic on Children’s Health and Well-Being

As millions of children across the nation prepare to go back to school this fall, many will face challenges due to ongoing health, economic, and social consequences of the pandemic. This brief examines how the COVID-19 pandemic has affected the health and well-being of children, explores recent policy responses, and considers what the findings means …

Back to School amidst the New Normal: Ongoing Effects of the Coronavirus Pandemic on Children’s Health and Well-Being Read More »

FDA authorises COVID booster jabs for at-risk people

The FDA has cleared the use of third dose of either the Pfizer/BioNTech or Moderna COVID-19 vaccines for people with weakened immune systems, but stopped short of a broader booster campaign. The emergency use authorisation (EUA) for the two mRNA-based vaccines has been amended so they can be used for solid organ transplant recipients or …

FDA authorises COVID booster jabs for at-risk people Read More »

UK cues up more Pfizer/BioNTech vaccines as price row looms

The UK government has started ordering COVID-19 vaccines for a 2022 booster campaign, including a 32 million-dose order for the Pfizer/BioNTech shot, even before third doses for 2021 have been given the go-ahead. A report in The Times claims that the government is paying £22 a dose – up from an earlier price of £18 …

UK cues up more Pfizer/BioNTech vaccines as price row looms Read More »

Covid-19 vaccines: the contracts, prices and profits

Raised charges and Covax deals on order books of Pfizer, BioNTech, Moderna and AstraZeneca Coronavirus – latest updates See all our coronavirus coverage Two US companies, Pfizer and Moderna, have raised the prices of their Covid-19 vaccines after data from clinical trials showed their mRNA formula was more effective than cheaper vaccines from Britain’s AstraZeneca …

Covid-19 vaccines: the contracts, prices and profits Read More »

UK orders extra Covid vaccines for autumn 2022 booster campaign

Pfizer reportedly asked to supply 35m more doses, with final go-ahead for this year’s programme still awaited Coronavirus – latest updates See all our coronavirus coverage Ministers have started ordering vaccines for a booster campaign in autumn 2022, with Pfizer reportedly being asked to supply the UK with a further 35m doses. The government has …

UK orders extra Covid vaccines for autumn 2022 booster campaign Read More »

SK Bio’s COVID vaccine will start phase 3 study versus AZ jab

South Korea’s SK Bioscience has been given the all-clear to start a phase 3 trial of its COVID-19 vaccine GBP510 that will compare the shot directly with AstraZeneca’s Vaxzevria. It is the first COVID-19 vaccine developed in South Korea to reach the pivotal trial stage, and from the earliest stages of its development has been …

SK Bio’s COVID vaccine will start phase 3 study versus AZ jab Read More »

Most Parents Don’t Want Their Schools to Require COVID-19 Vaccination, But Most Favor Requiring Masks for Unvaccinated Children and Staff

Worries about Long-Term and Serious Side Effects are Parents’ Top Concern; Hispanic and Black Parents Are More Likely than White Parents to Cite Access and Cost Issues As schools around the country prepare to reopen, a majority of parents of school-age children say they do not want their children’s schools to require students to get…More

KFF COVID-19 Vaccine Monitor: Parents and the Pandemic

This report examines attitudes and views of parents as children head back to school amidst the rise in COVID-19 cases due to the delta variant. Nearly half of parents of children ages 12-17, who are currently eligible to receive a COVID-19 vaccine, say their child has already been vaccinated or will get the vaccine right …

KFF COVID-19 Vaccine Monitor: Parents and the Pandemic Read More »

BioNTech says repeat doses may be better than modified COVID-19 jab

BioNTech has suggested that giving booster doses of its current Comirnaty (BNT162b2) COVID-19 vaccine may be a preferable strategy to modifying the Pfizer-partnered shot. The comments came on the German biotech’s second-quarter results call, during which BioNTech raised its forecasts for revenues it will book from sales of the vaccine to €15.9 billion (almost $19 …

BioNTech says repeat doses may be better than modified COVID-19 jab Read More »

Moderna COVID-19 jab sales rocket to $4.2 billion in second quarter

Moderna made a massive $4.2 billion from sales of just under 200 million doses of its COVID-19 vaccine, taking its tally since approval to around $6 billion from 302 million shots. The tally makes the SpikeVax (mRNA-1273) vaccine the second biggest seller behind Pfizer/BioNTech’s Comirnaty, which pulled in $7.8 billion in the second quarter and …

Moderna COVID-19 jab sales rocket to $4.2 billion in second quarter Read More »

Setting the record straight: Addressing common misconceptions about the COVID-19 vaccine

Bolstered by incredible progress in the fight against COVID-19, the biopharmaceutical industry continues to work around the clock to research, develop and manufacture vaccines and therapeutics to prevent and treat infection. COVID-19 vaccines have been credited with the steep decline in cases nationwide, but with cases again rising and a new threat from the highly …

Setting the record straight: Addressing common misconceptions about the COVID-19 vaccine Read More »

UK extends COVID vaccination to 16 and 17-year-olds

The UK government has confirmed that the national COVID-19 vaccination campaign will be extended to include 16 and 17-year-old children, to tackle an increase in spread of the virus in younger age groups. The moves comes on the back of new advice from the Joint Committee on Vaccine and Immunisation (JCVI), which has concluded that …

UK extends COVID vaccination to 16 and 17-year-olds Read More »

KFF COVID-19 Vaccine Monitor – July 2021

This report finds the share of adults who have either received a COVID-19 vaccine (67%) or say they will get vaccinated as soon as they can (3%) is little unchanged from June. A quarter of unvaccinated adults say they likely will get a vaccine by the end of they year, Unvaccinated adults are much less …

KFF COVID-19 Vaccine Monitor – July 2021 Read More »

Most Unvaccinated Adults Don’t Believe the Vaccines are Very Effective and See the Vaccines as a Greater Health Risk than COVID-19 Itself

Vaccinated Adults Are Nearly Twice as Likely as Unvaccinated Ones to Worry that New Variants Like Delta Will Worsen the Pandemic Nationally and Locally As public health officials struggle to boost vaccination rates nationally, the latest KFF COVID-19 Vaccine Monitor reports that a narrow majority (53%) of unvaccinated adults believe the vaccine poses a bigger…More

Germany confirms booster COVID jabs will start in September

Germany’s health ministry has said it will start offering booster COVID-19 vaccines to vulnerable people from next month, amid concerns about rising cases of the delta variant of the coronavirus. Health Minster Jens Spahn said the decision was also taken because of concerns that the immune response stimulated by COVID-19 vaccines may start to diminish …

Germany confirms booster COVID jabs will start in September Read More »

As Delta spreads, Pfizer and Moderna get set for a booster shot to profits

The firms are already taking the lion’s share of earnings from the market, as this week’s results will show Praised for preventing hundreds of thousands of deaths and allowing a return to more normal life, Covid vaccines will also substantially benefit some pharmaceutical companies. In June, analysts estimated the global market for the vaccines could …

As Delta spreads, Pfizer and Moderna get set for a booster shot to profits Read More »

COVID-19 Vaccine Breakthrough Cases Are Extremely Rare, According to KFF State Data Analysis

As COVID-19 cases increase along with spread of the more transmissible Delta variant, the effectiveness of COVID-19 vaccines continues to be an important topic. A new KFF analysis looks at COVID-19 vaccine “breakthrough cases,” when fully vaccinated individuals become infected, as well as hospitalizations and deaths, to see which states are providing data on breakthrough…More

AstraZeneca sales of Covid vaccine triple to $1.2bn in first half of 2021

Not-for-profit pledge sees British firm’s sales revenue fall significantly short of US rival Pfizer Coronavirus – latest updates See all our coronavirus coverage AstraZeneca’s Covid-19 vaccine has brought in $1.2bn (£900m) in the first half of this year, with sales tripling in the second quarter from the first – but its earnings remained significantly below …

AstraZeneca sales of Covid vaccine triple to $1.2bn in first half of 2021 Read More »

AZ’s COVID-19 jab sales top $1.2bn, but come at a loss

AstraZeneca said this morning that it has made $1.2 billion in sales from its COVID-19 vaccine Vaxzevria in the first half of this year, but making it available at no profit had weighed on its profit margins. R&D expenses leaped 28% in the period, an increase that AZ said was “primarily” a result of its …

AZ’s COVID-19 jab sales top $1.2bn, but come at a loss Read More »

Technology and empathy help make remote working a success for Elsevier

We at Elsevier were pleased to be one of five companies recognized for their ability to keep remote workers rooted in company culture in this recent Comparably article. Like many organizations during the pandemic, we had to quickly adapt to remote working on a large scale for our international workforce. As the article notes, “Elsevier …

Technology and empathy help make remote working a success for Elsevier Read More »

AZ says second COVID jab dose isn’t linked to rare clot reaction

A new analysis has suggested that the rare blood clot side effects linked to AstraZeneca’s COVID-19 vaccine Vaxzevria don’t occur after a second dose. The study in The Lancet examined cases of thrombosis with thrombocytopenia syndrome (TTS) from an AZ database encompassing around 5.62 million people who had received two doses of Vaxzevria in the …

AZ says second COVID jab dose isn’t linked to rare clot reaction Read More »

First published data backs CanSino’s inhaled COVID vaccine

Early-stage clinical data with CanSino Biologics’ inhaled COVID-19 vaccine show that it was able to stimulate neutralising antibodies against SARS-CoV-2 at a dose well below that required with intramuscular administration. Published in The Lancet, a phase 1 study conducted in China showed that a two-dose regimen of aerosolised Ad5-nCoV was similar to that achieved with …

First published data backs CanSino’s inhaled COVID vaccine Read More »

Boehringer takes alteplase to phase 3 for COVID, but drops antibody

Boehringer Ingelheim’s latecomer antibody therapy for COVID-19 has been side-lined, as the company focuses its attention on its thrombolytic drug alteplase, heading into a phase 3 programme later this year. The decision to discontinue development of BI 767551, an inhaled antibody, has been taken because of the “evolving landscape” in managing the pandemic including the …

Boehringer takes alteplase to phase 3 for COVID, but drops antibody Read More »

Major delay in federal government’s Novavax deal, with 51m doses not expected until 2022

Initially touted as a ‘primary’ vaccine to help immunise Australia by the end of this year, Novavax will now form part of the booster strategy One of the federal government’s key vaccine deals has been hit with major delays, with 51 million doses of Novavax originally due to arrive in the second half of this …

Major delay in federal government’s Novavax deal, with 51m doses not expected until 2022 Read More »

Rapid COVID immune status test launched in UK, Ireland

You’ve had your two COVID-19 jabs, but are you actually protected against infection? That’s a question that a fingerprick test launched today in the UK and Ireland could help to answer. The test – originally developed by US manufacturer Chembio Diagnostics – has been introduced into the UK and Irish markets by Guilford-based Luas Diagnostics …

Rapid COVID immune status test launched in UK, Ireland Read More »

Study finds jabs cut severe variant COVID disease after one shot

A real-world study carried out in Canada had found that COVID-19 vaccines from AstraZeneca, Pfizer/BioNTech and Moderna reduce the chances of being hospitalised or dying from variants of concern dramatically, even after a single dose. AstraZeneca’s Vaxzevria was found to 87% effective after against the delta variant, which is now thought to be one of …

Study finds jabs cut severe variant COVID disease after one shot Read More »

EMA starts review of latecomer GSK/Sanofi COVID-19 vaccine

The EMA has kicked off a rolling review of a COVID-19 vaccine from Sanofi and GlaxoSmithKline, which started a 35,000-patient phase 3 trial in May. The vaccine – now dubbed Vidprevtyn – is based on a recombinant protein antigen developed by Sanofi’s vaccines unit Sanofi Pasteur, and also includes an immune-boosting adjuvant developed by GSK …

EMA starts review of latecomer GSK/Sanofi COVID-19 vaccine Read More »

GSK plans £400m life sciences campus in Stevenage

Pharmaceuticals firm thinks creating cluster of companies at its site could result in up to 5,000 jobs GlaxoSmithKline is seeking to create a £400m campus in Stevenage for new life sciences companies that it believes could result in up to 5,000 jobs over the next decade. The pharmaceuticals company has kicked off a process to …

GSK plans £400m life sciences campus in Stevenage Read More »

Promoting global vaccine equity while protecting innovation

America’s biopharmaceutical companies have successfully researched, developed and distributed billions of doses of multiple vaccines and therapeutics to halt the spread of COVID-19. The availability of COVID-19 vaccines has shifted the trajectory of the pandemic and is undoubtedly saving lives. Further, the approval of the first ever mRNA vaccines has the potential to usher in …

Promoting global vaccine equity while protecting innovation Read More »

AZ, J&J tweaking COVID shots to reduce clotting risks; report

AstraZeneca and Johnson & Johnson are both exploring ways to modify their COVID-19 vaccines to minimise the risk of severe blood clotting reactions that are seen – albeit rarely – in some people receiving the jabs. At the same time, the UK’s National Institute for Health and Care excellence (NICE) is developing guidance to help …

AZ, J&J tweaking COVID shots to reduce clotting risks; report Read More »

Vaccine Monitor: Some Who Were Hesitant to Get a Vaccine in January Say They Changed Their Mind Because of Family, Friends and Their Personal Doctors

A new KFF COVID-19 Vaccine Monitor report finds that people who were initially hesitant to get a vaccine in January but ultimately did so often say that family, friends and their personal doctors helped change their minds. The report features a second round of interviews with a nationally representative sample of adults six months after…More

US officials call for more data on vaccine boosters as Pfizer pushes for third shot

• Pharma company presses case with senior health officials • WHO urges priority for nations with low Covid vaccination rates Pfizer, the pharmaceutical company that created one of the first Covid-19 vaccines to be approved, has been making a hard sell for emergency approval of boosters – additional doses given to those already vaccinated, especially …

US officials call for more data on vaccine boosters as Pfizer pushes for third shot Read More »

Pfizer pushes for booster shots as WHO says greed is driving vaccine disparities

• Pharmaceutical company seeks FDA approval for third dose • Companies urged to instead prioritise less wealthy countries After a sharp increase in US Covid cases and amid fears of a surge of the Delta variant, Pfizer on Monday said it was seeking federal authorisation for third doses of its Covid-19 vaccine to be delivered …

Pfizer pushes for booster shots as WHO says greed is driving vaccine disparities Read More »

Morrison government silent on contact with Pfizer global chief after Kevin Rudd intervenes in vaccine talks

Under fire for his government not reaching out to the pharmaceutical giant’s international head, health minister Greg Hunt also avoided naming the former Labor PM Scott Morrison and federal health minister Greg Hunt have not denied claims that they failed to press Australia’s case for more vaccine doses directly with Pfizer’s global chief, after revelations …

Morrison government silent on contact with Pfizer global chief after Kevin Rudd intervenes in vaccine talks Read More »

EMA finds possible link between mRNA COVID jabs and myocarditis

The EU medicines regulator has said that there is some evidence to suggest a possible link between mRNA-based vaccines for COVID-19 and rare cases of heart inflammation.  According to the EMA’s pharmacovigilance risk assessment committee (PRAC), labelling for Pfizer/BioNTech’s Comirnaty and Moderna’s Spikevax should be updated to reflect “very rare cases” of myocarditis and pericarditis …

EMA finds possible link between mRNA COVID jabs and myocarditis Read More »

Eyeing delta surge, Pfizer will file COVID-19 booster next month

With the COVID-19 delta variant has become the dominant strain circulating in the US, Pfizer and BioNTech have said they will ask the FDA and other regulators to approve a third dose of their Comirnaty vaccine to guard against a winter surge in cases.  The two companies have revealed data from an ongoing trial of …

Eyeing delta surge, Pfizer will file COVID-19 booster next month Read More »

Philip Morris International makes £1bn offer for pharma firm Vectura

Tobacco company strikes deal for British firm developing pioneering inhaled treatment for Covid-19 Coronavirus – latest updates See all our coronavirus coverage Philip Morris International, the tobacco company and maker of Marlboro cigarettes, has struck a £1bn deal to buy Vectura, the British pharmaceutical company developing a pioneering inhaled treatment for Covid-19. The £1.04bn offer …

Philip Morris International makes £1bn offer for pharma firm Vectura Read More »

Gates Foundation backs COVID R&D at AI firm Exscientia

Artificial intelligence-based drug discovery company Exscientia is stepping up its search for new COVID-19 medicines, thanks to an award by the Bill & Melinda Gates Foundation.  The $1.5 million grant will be used to develop a new class of small-molecule inhibitors of Mpro , a protease enzyme essential for the replication of the SARS-CoV-2 virus. …

Gates Foundation backs COVID R&D at AI firm Exscientia Read More »

Oxford drugs firm gains $1.5m Gates grant for Covid-19 therapy

Exclusive: Exscientia to use AI in proposed fast-track development of ‘low-cost’ pill for Sars viruses Coronavirus – latest updates See all our coronavirus coverage Exscientia, an Oxford-based firm that uses artificial intelligence to develop medicines, has won a $1.5m grant from the Bill & Melinda Gates Foundation to create a Covid-19 treatment that also works …

Oxford drugs firm gains $1.5m Gates grant for Covid-19 therapy Read More »

Israel says Pfizer jab less effective against COVID-19 delta

The Israeli Ministry of Health has reported data suggesting that the efficacy of the Pfizer/BioNTech COVID-19 vaccine has become less effective at preventing the spread of the coronavirus after the emergence of the delta variant. The vaccine still seems to be able to prevent hospitalisation and severe cases of COVID-19, but its efficacy in preventing …

Israel says Pfizer jab less effective against COVID-19 delta Read More »

Unsure whether to get a COVID-19 jab? Just ask Vira!

With COVID-19 vaccine hesitance an increasing concern in the US, researchers at Johns Hopkins have developed a chatbot – called Vira – that aims to explode myths about vaccination. Worried that COVID-19 vaccines have serious side effects that are being covered up, or vaccines are being used to track the population? Or just uncertain whether …

Unsure whether to get a COVID-19 jab? Just ask Vira! Read More »

Ocugen preps filings for COVID-19 vaccine Covaxin on new data

Armed with new data from its development partner Bharat Biotech, Ocugen is planning to press ahead with plans to file for approval of their COVID-19 vaccine Covaxin in the US and Canada. Covaxin has already been approved for restricted emergency use in India, getting the green light in January months before the final results from …

Ocugen preps filings for COVID-19 vaccine Covaxin on new data Read More »

Centre Court ovations, limbo-dancing grans – it’s all been humbling, say Oxford vaccine creators

Sarah Gilbert and Catherine Green tell of their pioneering vaccine work but warn the battle is far from over Coronavirus – latest updates See all our coronavirus coverage Sarah Gilbert’s experiences at Wimbledon last week clearly had a profound impact on the medical researcher – though it was not the standing ovation that the vaccine …

Centre Court ovations, limbo-dancing grans – it’s all been humbling, say Oxford vaccine creators Read More »

Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery

As we head into the Fourth of July weekend, Americans are reemerging from the COVID-19 pandemic with heightened hopes and confidence in a strong U.S. recovery. The COVID-19 vaccines have been credited with the steep decline in cases nationwide as we reach the lowest rates since the earliest stages of the pandemic. Reliance on safe, …

Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery Read More »

Million Pfizer jabs face being dumped after Israel-UK swap deal fails

Israel says technical issues have scuppered deal to give UK Covid vaccines expiring on 30 July Coronavirus – latest updates See all our coronavirus coverage More than a million Pfizer/BioNTech vaccine doses held in Israel that are due to expire at the end of July may be thrown away after attempts to broker a swap …

Million Pfizer jabs face being dumped after Israel-UK swap deal fails Read More »

Zydus Cadila nears world-first human plasmid DNA vaccine approval

Zydus Cadila has filed for emergency use approval (EUA) in India of its plasmid DNA-based vaccine for COVID-19, which if given a green light could become the first shot of its type to be cleared for widespread use in humans.  Leaving aside the possible technological milestone, the ZyCOV-D vaccine has a few characteristics that could …

Zydus Cadila nears world-first human plasmid DNA vaccine approval Read More »

UK body recommends COVID booster campaign in autumn

The UK’s Joint Committee on Vaccination and Immunisation (JCVI) has recommended that the NHS should start a COVID-19 booster shot programme in September, to run alongside the annual flu vaccine drive.  The programme should run in two stages, initially targeting elderly and vulnerable people and frontline health and social care workers like the initial vaccination …

UK body recommends COVID booster campaign in autumn Read More »

UK body recommends COVID booster campaign in autumn

The UK’s Joint Committee on Vaccination and Immunisation (JCVI) has recommended that the NHS should start a COVID-19 booster shot programme in September, to run alongside the annual flu vaccine drive.  The programme should run in two stages, initially targeting elderly and vulnerable people and frontline health and social care workers like the initial vaccination …

UK body recommends COVID booster campaign in autumn Read More »

The Oxford vaccine: the trials and tribulations of a world-saving jab

Amid bemusement from scientists at the deluge of often undeserved criticism, the Guardian pieces together the story behind the vaccine’s successes and failures Coronavirus – latest updates See all our coronavirus coverage In January 2020, when most of the world slept soundly in ignorance of the pandemic coming its way, a group of scientists at …

The Oxford vaccine: the trials and tribulations of a world-saving jab Read More »

More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities

We are in a new era of medicine where groundbreaking biopharmaceutical research and development is transforming medicine, but these innovations are meaningless if they don’t reach patients, including those in underserved communities. Health disparities are not new, but the COVID-19 pandemic put a spotlight on long-standing health inequities that affect diverse racial and ethnic communities …

More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities Read More »

More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities

We are in a new era of medicine where groundbreaking biopharmaceutical research and development is transforming medicine, but these innovations are meaningless if they don’t reach patients, including those in underserved communities. Health disparities are not new, but the COVID-19 pandemic put a spotlight on long-standing health inequities that affect diverse racial and ethnic communities …

More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities Read More »

Moderna, Pfizer or AstraZeneca? The ridiculous, diverting rise of vaccine envy

Casual vaccine chat is today’s only form of small talk, so it’s not surprising it would take a lightheartedly tribal turn. Ultimately, of course, gratitude is at the heart of the conversation Last week, I had cause to go searching for images of men getting vaccinated (it’s not a fetish – it was for work) …

Moderna, Pfizer or AstraZeneca? The ridiculous, diverting rise of vaccine envy Read More »

Western countries must share Covid vaccines – if only for the sake of their GDP

Optimistic forecasts about ‘bouncing back’ will only come true if new variants do not close borders and devastate trade again Coronavirus – latest updates See all our coronavirus coverage The world economy is on course to bounce back from the pandemic with a momentum that will carry through to next year and beyond. This prediction, …

Western countries must share Covid vaccines – if only for the sake of their GDP Read More »

Covid jabs for billions of humans will earn their makers billions of dollars

We look at the drug firms – led by Pfizer and Moderna – that are set to profit most in an unprecedented global vaccination drive Coronavirus – latest updates See all our coronavirus coverage Drugmakers led by US firms Pfizer and Moderna stand to make tens of billions of dollars from their Covid-19 vaccines this …

Covid jabs for billions of humans will earn their makers billions of dollars Read More »

EU fails in court action to secure urgent 120m doses of Oxford Covid vaccine

But Brussels court says AstraZeneca should earlier have used UK plants to fulfil EU deliveries Coronavirus – latest updates See all our coronavirus coverage The EU has failed in a legal attempt to secure an urgent 120m vaccine doses from AstraZeneca by the end of this month, while securing a judgment that sites in Oxford …

EU fails in court action to secure urgent 120m doses of Oxford Covid vaccine Read More »

EU fails in court action to secure urgent 120m doses of Oxford Covid vaccine

But Brussels court says AstraZeneca should earlier have used UK plants to fulfil EU deliveries Coronavirus – latest updates See all our coronavirus coverage The EU has failed in a legal attempt to secure an urgent 120m vaccine doses from AstraZeneca by the end of this month, while securing a judgment that sites in Oxford …

EU fails in court action to secure urgent 120m doses of Oxford Covid vaccine Read More »

EU and AZ both claim victory in COVID jab supply lawsuit

A court in Belgium has ordered AstraZeneca to deliver additional doses of its COVID-19 vaccine to EU member states by 27 September, although far fewer than the amount sought by the European Commission. The EU had requested 120 million doses by the end of this month and 300 million by end-September, but the judge in …

EU and AZ both claim victory in COVID jab supply lawsuit Read More »

Americans 12 years of age and older are eligible for COVID-19 vaccines

Last month, the U.S. Food and Drug Administration (FDA) granted an expansion of an emergency use authorization on one of the COVID-19 vaccines allowing Americans 12-15 years of age and older to be eligible to receive the one of the COVID-19 vaccines. Following this positive news, the Advisory Committee on Immunization Practices also recommended this …

Americans 12 years of age and older are eligible for COVID-19 vaccines Read More »

White House pledges $3 billion war chest for COVID antivirals

The Biden Administration has said it will allocate $3 billion of its pandemic rescue plan to the development of a new generation of antiviral therapies for COVID-19, as well as future viral threats. The plan was announced today by National Institute of Allergy and Infectious Diseases (NIAID) director and chief medical advisor Anthony Fauci, who …

White House pledges $3 billion war chest for COVID antivirals Read More »

AstraZeneca vaccine price pledge omits some poor countries, contract shows

Exclusive: firm could charge more in places such as Zimbabwe and Sri Lanka once Covid pandemic is over Coronavirus – latest updates See all our coronavirus coverage AstraZeneca can charge a higher price for its Covid-19 vaccine in dozens of poor countries once the pharmaceutical company decides the pandemic has ended, according to a copy …

AstraZeneca vaccine price pledge omits some poor countries, contract shows Read More »

CureVac hit hard as its COVID jab fails to make the grade

CureVac has just had a harsh reminder of the perilous nature of drug development, after reporting that its mRNA-based COVID-19 vaccine was just 47% effective in its 40,000-subject phase 3 trial. That is below the threshold efficacy level for a vaccine laid out by the World Health Organisation (WHO) in the early stages of the …

CureVac hit hard as its COVID jab fails to make the grade Read More »

Regeneron drug saves lives in severe COVID-19, but it’s not for all

People who cannot generate an effective immune response against COVID-19 can be protected with an infusion of Regeneron’s antibody therapy REGN-COV, according to new data from the UK RECOVERY trial. The therapy significantly reduced the risk of death, the length of hospital stay and the need for a ventilator in the study, which involved around …

Regeneron drug saves lives in severe COVID-19, but it’s not for all Read More »

AZ’s COVID jab tackles delta variant, but antibody fails clinical trial

The delta variant of COVID-19 may be holding back the lifting of lockdown restrictions in the UK, but there is some good news – the AstraZeneca/Oxford University vaccine seems to offer a high level of protection against it. Real-world data from Public Health England (PHE) suggests that the vaccine prevents 92% of hospitalisations in patients …

AZ’s COVID jab tackles delta variant, but antibody fails clinical trial Read More »

Hospitality firms urgently need clarity from Sunak about £2.5bn of unpaid rent

Giving landlords and tenants six months to work out a deal on arrears could stop an wave of bankruptcies in the sector If it really is a case of “one more heave” on vaccinations before restrictions on the hospitality sector can be eased, what’s the best way to ensure the country’s pubs, restaurants and nightclubs …

Hospitality firms urgently need clarity from Sunak about £2.5bn of unpaid rent Read More »

Novavax unveils phase 3 COVID jab data, but has it missed the boat in US?

The top-line phase 3 data for Novavax’ COVID-19 vaccine look good, with a 90% overall efficacy rate, but a dip in its share price indicates investors fear it could be too late for the programme. Novavax’ price spiked 9% after the data were announced today, but fell back just as quickly, despite the company’s assertions …

Novavax unveils phase 3 COVID jab data, but has it missed the boat in US? Read More »

J&J must ditch 60m COVID jabs made at US plant, but 10m are okay, says FDA

The failings at a Baltimore, US factory making Johnson & Johnson’s COVID-19 vaccine mean that millions of doses of the shot will have to be jettisoned, according to an FDA update. The problems at the plant run by contract manufacturer Emergent BioSolutions first emerged a few weeks ago, after an FDA inspection uncovered a string …

J&J must ditch 60m COVID jabs made at US plant, but 10m are okay, says FDA Read More »

Drop Covid vaccine patent rules to save lives in world’s poorest countries, Britain and Germany told

G7 summit hears move would slash the cost of jabs and accelerate the rollout of programmes across the developing world Britain and Germany were last night under intense pressure to drop their resistance to proposals that would slash the cost of Covid-19 vaccines, following accusations that an agreement at the G7 summit to fund a …

Drop Covid vaccine patent rules to save lives in world’s poorest countries, Britain and Germany told Read More »

June 18 Web Event: Asian Immigrant Experiences with Racism, Immigration-related Fears, and the COVID-19 Pandemic

While the country has collectively experienced health and economic difficulties with the COVID-19 pandemic, certain groups have experienced a disproportionate impact. The Asian American community has had to cope with the burden of pandemic-related racism and, as one of the fastest growing immigrant communities in the nation, immigration-related fears due to policy and regulatory action…More

PhRMA hosts first public workshop on clinical trial diversity

This week, 500+ health care and community members from over 150 organizations came together at PhRMA’s first stakeholder workshop focused on improving diversity in clinical trials. At the virtual workshop, titled “Partnering for Health Equity: Advancing Research Through Representative Clinical Trials,” participants joined breakout discussions, panels and facilitated conversations designed to pressure test actionable ideas …

PhRMA hosts first public workshop on clinical trial diversity Read More »

Covid vaccine programme for developing countries could cost $6.5bn

If pharmaceutical companies do not waive intellectual property rights the cost could reach $80bn Coronavirus – latest updates See all our coronavirus coverage The world’s developing countries could be vaccinated against Covid-19 at a cost of just $6.5bn (£4.6n) if pharmaceutical companies waive their intellectual property rights, under plans being outlined at the G7 summit …

Covid vaccine programme for developing countries could cost $6.5bn Read More »

Ocugen gets a black eye as FDA denies emergency OK for COVID jab

Ocugen is the first company to be affected by the FDA’s recent decision to raise the bar on emergency use authorisations for COVID-19 medicines, and will have to file for full approval of its vaccine candidate. That will hold back the biotech’s Covaxin shot by several months, and the delay put pressure on Ocugen’s share …

Ocugen gets a black eye as FDA denies emergency OK for COVID jab Read More »

An Update on Global Availability of COVID-19 Vaccines from Editor of The Lancet

In the U.S., the COVID-19 vaccine roll-out has moved at a strong pace, with about half of Americans now having received at least one shot. While many of the most motivated people have been able to get vaccinated by now, plenty of others still have questions. They may wonder if the vaccines are safe in …

An Update on Global Availability of COVID-19 Vaccines from Editor of The Lancet Read More »

US orders 500m Pfizer/BioNTech COVID jabs for developing nations

The US government will buy 500 million more doses of the Pfizer/BioNTech COVID-19 vaccine that will be given to around 100 countries via the COVAX donation programme over the next two years. Pfizer and BioNTech are providing 200 million doses this year, and another 300 million in the first half of 2022, at a not-for-profit …

US orders 500m Pfizer/BioNTech COVID jabs for developing nations Read More »

More research funding needed to avoid drug-resistant pandemic, warns report

Smaller firms are developing most antibiotics targeting superbugs but often at risk of bankruptcy Small drugmakers and biotech firms that are developing the bulk of new antibiotics need far more financial support, according to a new report, which warned that without these life-saving medicines there could be a pandemic of drug-resistant infections, worse than Covid-19. …

More research funding needed to avoid drug-resistant pandemic, warns report Read More »

Study links AstraZeneca COVID-19 shot to bleeding disorder ITP

Researchers in Scotland have identified a possible link between the Oxford University/AstraZeneca COVID-19 and a mostly mild and generally treatable bleeding disorder. The scientists examined real-world public health data from all individuals in Scotland who received either the AZ or Pfizer/BioNTech vaccines up until 14 April and found a possible association between the AZ shot …

Study links AstraZeneca COVID-19 shot to bleeding disorder ITP Read More »

Merck nabs $1.2 billion order for oral COVID antiviral from US

The US government has placed an order with Merck & Co to buy 1.7 million courses of its antiviral therapy molnupiravir for COVID-19, assuming it gets approved for use by the FDA. The $1.2 billion deal is among the largest placed by the federal government for a COVID-19 medicine, reflecting molnupiravir’s potential as an orally-active …

Merck nabs $1.2 billion order for oral COVID antiviral from US Read More »

Thailand starts Covid vaccine drive using jabs made by king’s firm

Country aims to vaccinate 70% of people this year but experts express doubts amid supply concerns Coronavirus – latest updates See all our coronavirus coverage Thailand has started its Covid vaccination campaign amid concerns over the supply of doses, which are mainly being produced locally by a royal-owned company that has no prior experience of …

Thailand starts Covid vaccine drive using jabs made by king’s firm Read More »

Study finds “alarming” hike in antidepressant costs during COVID-19

Researchers in the UK have found that there was a four million rise in prescriptions for antidepressants in England during 2020, adding £139 million to NHS costs. The team from the University of Huddersfield said the findings highlight an “urgent need” for new mental health strategies to make sure antidepressants are being used appropriately, particularly …

Study finds “alarming” hike in antidepressant costs during COVID-19 Read More »

Fears of side-effects fuel reluctance to get Covid jabs, survey finds

Imperial College London survey in 15 countries also reveals worries that vaccines had not been tested enough Coronavirus – latest updates See all our coronavirus coverage Most people who are reluctant to be vaccinated against Covid are worried about side-effects and whether the vaccines have been adequately tested, a survey in 15 countries has shown. …

Fears of side-effects fuel reluctance to get Covid jabs, survey finds Read More »

Two-Thirds of the Public Say the U.S. Should Play a Major Role in Distributing COVID-19 Vaccines Globally, But Not Most Republicans

With increased attention to the global need for COVID-19 vaccines and the Biden administration’s announcement today about how it plans to distribute the first portion of the 80 million doses it will share by the end of this month, the latest KFF Health Tracking Poll finds that two-thirds of the public (66%) say that the…More

KFF Health Tracking Poll – May 2021: Prescription Drug Prices Top Public’s Health Care Priorities

The latest KFF Health Tracking Poll explores the public’s views on the U.S. role in distributing COVID vaccines to other countries, health care priorities for Congress, prescription drug regulations and price negotiations, and affordability changes in the COVID-19 relief bill.

UK is talking to AstraZeneca about beta variant COVID jab

The UK government is talking to AstraZeneca about ordering additional doses of its COVID-19 vaccine that will target the beta variant of SARS-CoV-2 virus first identified in South Africa, according to Health Secretary Matt Hancock. The AZ/Oxford University vaccine and other shots from Pfizer/BioNTech and Moderna are known to have less efficacy against the beta …

UK is talking to AstraZeneca about beta variant COVID jab Read More »

EU’s COVID jab certificate scheme goes live in seven countries

The first batch of EU countries have started recognising the vaccination status of travellers using digital vaccine certificates as the bloc moves towards freeing up travel ahead of the summer period. Germany, Greece, Bulgaria, Czech Republic, Denmark, Croatia and Poland are the first to start using the scheme, which will allow people who have been …

EU’s COVID jab certificate scheme goes live in seven countries Read More »

Moderna ramps up EU COVID jab capacity via Lonza deal

Capacity to supply Moderna’s COVID-19 vaccine in Europe could be swelled by round 300 million doses a year, following an agreement to set up a new production line at contract manufacturer Lonza. The increased capacity depends on Moderna getting approval for a half dose of an updated version of the mRNA-1273 vaccine – targeting new …

Moderna ramps up EU COVID jab capacity via Lonza deal Read More »

Janssen COVID jab cleared in UK as fears of third wave mount

With concern already growing about a possible third wave of COVID-19 infections, the UK has cleared the use of a fourth vaccine from Johnson & Johnson’s Janssen division. The Medicines and Healthcare products Regulatory Agency (MHRA) gave a green light to the single-dose Ad26.COV2.S vaccine in people aged 18 and over by referencing the decision …

Janssen COVID jab cleared in UK as fears of third wave mount Read More »

MPs tell Johnson: you have a duty to help vaccinate the world

Exclusive: group urges prime minister to tackle ‘desperate shortage’ in developing nations Coronavirus – latest updates See all our coronavirus coverage Boris Johnson has a “moral duty” to immediately start matching each vaccine administered at home with a donated dose to poorer countries across the world, a cross-party group of MPs and peers has said. …

MPs tell Johnson: you have a duty to help vaccinate the world Read More »

Vaccine Monitor: Vaccination Rates Continue to Inch Upwards Across Groups, Especially Among Hispanic Adults, But Few Who Are Eager to Get a Shot Remain Unvaccinated

4 in 10 Parents Say Their Adolescent Children Have Already Gotten a Shot or Will Do So Right Away; One Quarter of Parents of Children Under 12 Will Get Them Vaccinated as Soon as They Are Eligible Few Unvaccinated Adults Say that CDC’s Guidelines for Vaccinated Adults Make Them More Likely to Get a Shot…More

KFF COVID-19 Vaccine Monitor: May 2021

This report shows continued steady progress in vaccine uptake, with 62% of adults saying they’ve gotten at least one dose of a COVID-19 vaccine, though few who are eager remain unvacciinated. In addition, 41% of parents of children ages 12-17 say their child has already received at least one dose or that they will do …

KFF COVID-19 Vaccine Monitor: May 2021 Read More »

GSK, Sanofi eye Q4 approval as COVID jab starts phase 3

GlaxoSmithKline’s COVID-19 drive has advanced on two fronts, with the start of phase 3 trials of its Sanofi-partnered vaccine candidate as well as an FDA emergency approval for antibody sotrovimab, developed with Vir Biotech. GSK and Sanofi think they could be on track for approval of the recombinant protein-based vaccine – delivered with GSK’s immune-response …

GSK, Sanofi eye Q4 approval as COVID jab starts phase 3 Read More »

Taiwan accuses China of interfering with Covid vaccine deals

President says agreement with German firm BioNTech has been delayed after Beijing intervention Coronavirus – latest updates See all our coronavirus coverage Taiwan’s president has accused China of interfering in its vaccine acquisition programme, as the island continues to battle hundreds of daily new cases of Covid-19 with low supplies of vaccines. Taiwan has received …

Taiwan accuses China of interfering with Covid vaccine deals Read More »

German scientists say they can help improve Covid vaccines to prevent blood clots

AstraZeneca and Johnson & Johnson jabs have caused rare blood clots but scientists say they can be redesigned to avoid problem Coronavirus – latest updates See all our coronavirus coverage A team of German scientists believe that they have worked out why some people given the AstraZeneca and Johnson & Johnson vaccines against Covid-19 develop …

German scientists say they can help improve Covid vaccines to prevent blood clots Read More »

EU asks court to fine AstraZeneca over missing COVID jab shipments

Lawyers for the European Commission asked a court in Brussels today to fine AstraZeneca millions of euros for its “obvious”  failure to meet the terms of its contract to supply COVID-19 vaccines to the EU. Rafael Jafferali Counsel for the Commission – Rafael Jafferali – insisted during the hearing at the Brussels Court of First …

EU asks court to fine AstraZeneca over missing COVID jab shipments Read More »

Belgium halts dosing of J&J COVID vaccine in under 41s after death

Belgium’s Ministry of Health has paused dosing of people under the age of 41 with Johnson & Johnson’s one-shot COVID-19 vaccine, following the death of a woman from what appeared to be a blood clot-related condition.  The unnamed woman – who was under the age of 40 – died on 21 May after being admitted …

Belgium halts dosing of J&J COVID vaccine in under 41s after death Read More »

The Pandemic’s Impact on Children’s Mental Health

The pandemic has taken a heavy toll on the nation’s mental health, and a new issue brief shows that children are also facing worsening emotional and cognitive health. The brief examines factors contributing to worsening mental health and substance use outcomes among children and adolescents during the pandemic, looking closely at those who are at…More

UK pharmaceutical firm Ventura agrees to £958m takeover deal

Private equity firm Carlyle Group to buy company that is developing inhaled treatment for Covid-19 Coronavirus – latest updates See all our coronavirus coverage The British pharmaceutical company Vectura Group, which is developing a pioneering inhaled treatment for Covid-19, has agreed a £958m takeover by Carlyle Group as it looks set to become the latest …

UK pharmaceutical firm Ventura agrees to £958m takeover deal Read More »